期刊文献+

基于报告基因的抗CD20单克隆抗体ADCC生物学活性测定方法的建立 被引量:10

Development of a novel reporter gene method for determination of ADCC potency of anti-CD20 monoclonal antibody
原文传递
导出
摘要 利用Jurkat/NFAT-luc+FcγRIIIa转基因细胞系作为效应细胞,WIL2-S细胞系作为靶细胞,通过荧光素酶检测系统(Bio GloTM Luciferase Assay System)进行抗CD20单抗的ADCC生物学活性检测,并对实验条件进行优化及方法学验证。结果显示抗CD20单抗在该方法中存在量效关系,且符合四参数方程式:y=(A-D)/[1+(X/C)B]+D。方法经优化确定靶细胞为WIL2-S细胞,抗体稀释浓度为18 000 ng·m L-1,1∶5倍的稀释倍数,效靶比为6∶1,诱导时间为6 h。该方法具有良好的专属性,8次独立实验的回归分析、线性及平行性均通过统计学检验;4个不同稀释组回收率样本经3次测定,相对效价分别为(44.39±3.93)%、(72.74±2.78)%、(128.28±7.01)%和(168.19±2.70)%,变异系数均小于10%,对应回收率分别为(88.78±7.85)%、(96.99±3.70)%、(102.63±5.61)%和(112.12±1.80)%。本研究利用转基因细胞法成功建立抗CD20单抗ADCC生物学活性检测方法,该方法专属性强、重复性好,准确性高,可作为抗CD20单抗ADCC生物学活性的常规检测方法。 The biological activity of ADCC by anti-CD20 monoclonal antibody was determined by BioGlo Tra Luciferase Assay System using Jurkat/NFAT-luc+FcTRIIIa cell line as effector cell and WIL2-S cell line as target cell. The developed method was verified for specificity, precision and accuracy. Anti-CD20 monoclonal antibody showed a dose-response mode by the developed method, and the determination result complied with the following four-parameter equation: y= (A-D) / [ 1 + (X/C)B] +D. The optimized parameters of the method were determined including the antibodies diluted concentration (18 000 ng·mL^-l), dilution rate (1 : 5), the ratio of effector cell and target cell (6 : 1), and induction time (6 h). The values of eight independent tests have passed a statistical test for curve regression analysis, linear or parallelism, which showed the method possessed good specificity. Four different dilute groups of recovery rates sample were determined for 3 times, and the result showed mean relative potencies of (44.39±3.93)%, (72.74±2,78)%, (128.28±7.01)% and (168.19±2.70)% respectively, with a variation coefficient of less than 10%, and the recoveries of (88.78 ±7.85)%, (96.99±3.70)%,(102.63± 5.61)% and (112.12 ± 1.80)% respectively. A novel reporter gene method for determination of biological activity of ADCC by anti-CD20 monoclonal antibody was successfully developed, which showed strong specificity, good reproducibility and high accuracy, and might be used routinely.
出处 《药学学报》 CAS CSCD 北大核心 2015年第1期94-98,共5页 Acta Pharmaceutica Sinica
基金 国家"重大新药创制"科技重大专项资助项目(2014ZX09304311-001 2012ZX09304010) 中国食品药品检定研究院中青年发展研究基金资助项目(2012B6)
关键词 抗CD20单克隆抗体 ADCC 生物学活性 anti-CD20 monoclonal antibody ADCC biological activity
  • 相关文献

参考文献1

二级参考文献11

  • 1Lau SC, Rosa DI), Jayson G. Technology evaluation: VEGF Trap (cancer), regeneron/sanofi-aventis. Curr Opin Mol Ther, 2005, 7 (5): 493-501.
  • 2Holash J, Davis S, Papadopoulos N, et al. VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci USA, 2002, 99 (17): 11393-11398.
  • 3Riely GJ, Miller VA. Vascular endothelial growth factor trap in non small cell lung cancer. Clin Cancer Res, 2007, 13 (15pt2): s4623-s4627.
  • 4Do DV, Nguyen QD, Shah SM, et al. An exploratory study of the safety, tolerability and bioactivity of a single intravitreal injection of vascular endothelial growth factor Trap-Eye in patients with diabetic maeular oedema. Br J Ophthalmol, 2009, 93 (2): 144-149.
  • 5Kaiser PK. Vascular endothelial growth factor Trap-Eye for diabetic macular oedema. Br J Ophthalmol, 2009, 93 (2): 135-136.
  • 6Aflibercept: AVE 0005, AVE 005, AVE0005, VEGF Trap-Regeneron, VEGF Trap (RIR2), VEGF Trap-Eye. Drugs RD, 2008, 9 (4): 261-269.
  • 7Barakat MR, Kaiser PK. VEGF inhibitors for the treatment of neovascular age-related macular degeneration. Expert Opin Investig Drugs, 2009, 18 (5): 637-646.
  • 8Gomez-Manzano C, Holash J, Fueyo J, et al. VEGF Trap induces antiglioma effect at different stages of disease. Neuro Oncol, 2008, 10 (6): 940-945,.
  • 9Nguyen QD, Shah SM, Hafiz G, et al. A phase I trial of an IV-administered vascular endothelial growth factor trap for treatment in patients with choroidal neovascularization due to age-related macular degeneration. Ophthalmology, 2006, 113 (9) : 1522e 1-1522e14.
  • 10Lee D, Heymaeh JV. Emerging antiangiogenic agents in lung cancer. Clin Lung Cancer, 2006, 7 (5): 304-308.

共引文献10

同被引文献54

  • 1田生和,王大坤.细胞ELISA法的建立及应用[J].中国生物制品学杂志,1992,5(1):27-29. 被引量:3
  • 2钱卫珠,侯盛,李博华,杨扬,王晓芸,王荣福,王皓.抗HER2人源化单克隆抗体体内外抗肿瘤活性评价方法的建立[J].第二军医大学学报,2005,26(5):484-487. 被引量:2
  • 3张颖妹,王应,徐茜梅,吕冰峰,马大龙.利用NF-κB转录活性萤光素酶报告系统检测白细胞介素1及白细胞介素1受体拮抗剂的生物活性[J].北京大学学报(医学版),2006,38(6):653-656. 被引量:2
  • 4张永.干扰素的分子生物学机制研究进展[J].海峡药学,2007,19(1):7-10. 被引量:9
  • 5张峰.Di Fi细胞增殖抑制法测定抗表皮生长因子受体单克隆抗体的生物学活性.中国生物制品学杂志,2011,20(5):607-609.
  • 6Cullen S P,Martin S J.Caspase activation pathways:some recent progress.Cell Death and Differentiation,2009,16(2):935-938.
  • 7Paul V Beum,Margaret A,Lindorfer E,et al.Within peripheral blood mononuclear cells,antibody-dependent cellular cytotoxicity of rituximab-opsonized daudi cells is promoted by NK cells and inhibited by monocytes due to shaving.The Journal of Immunology,2008,181(4):2916-2924.
  • 8Louise L,Alex B,Xu R R,et al.Bioactivity determination of native and variant forms of therapeutic interferons.Journal of Biomedicine and Biotechnology,2011,1:174615-174625.
  • 9Yu L,Rao C,Shi X,et al.A novel bioassay for the activity determination of therapeutic human brain natriuretic peptide(BNP).PLo S One,2012,7(11):e49934-e49942.
  • 10Yang Y S,Zhou Y,Yu L,et al.A novel reporter gene assay for recombinant human erythropoietin(r Hu EPO)pharmaceutical products.Journal of Pharmaceutical and Biomedical Analysis,2014,100(9)316-321.

引证文献10

二级引证文献26

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部